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agents. ArAbstract A series of novel substituted 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids (1a–1j)
and its methyl esters (2a–2f) were synthesized and examined for their antiproliferative effects
against three breast cancer cell lines (MDA-MB231, MDA-MB468 and MCF7) in vitro. Most of
the compounds exhibited comparable or greater antiproliferative effects than the reference com-
pound cisplatin. Compound 2e bearing 5-ﬂuoro-2-hydroxyphenyl substituent was found to be
the most active derivative of the series with GI50 values of 6.23, 4.09 and 0.18 lM against MDA-
MB468, MDA-MB231 and MCF7 breast cancer cell lines, respectively. Our ﬁndings described here
exemplify the usefulness of the title compounds as a lead for the development of more effective can-
cer therapeutics for the treatment of breast cancer.
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Cancer is still one of the leading causes of death worldwide. The
death rate from various types of cancer continues to rise world-
wide with an estimated 12 million deaths in 2030 (Solomon
et al., 2009; Patel et al., 2011).One in ten of all new types of cancer
diagnosed around the world each year is breast cancer and is the
most common cancer in women in both developing and devel-
oped countries (www.who.int/cancer/detection/breastcancer/ing Saud University.
valuation of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids and its methyl
p://dx.doi.org/10.1016/j.arabjc.2013.07.003
2 C. Karthikeyan et al.en). Estrogen receptor (ER)-negative breast cancer accounts for
approximately 30% of all breast cancer diagnosed (Somers-Ed-
gar et al., 2011;Yadav et al., 2011;Farag et al., 2010).Chemother-
apy has been themost frequently used treatment for breast cancer
and other cancers till date. However, some normal proliferating
cells are destroyed as well by this method of treatment (Wang
et al., 2009). Hence, there is an intense worldwide search for iden-
tifying new drugs that are more effective and safe for the preven-
tion and treatment of cancer.
A survey of the literature in this area shows that many het-
erocyclic scaffolds have been investigated as anti-breast cancer
agents (Al-Said et al., 2011). Benzimidazoles are a useful struc-
tural motif for the development of molecules of pharmaceuti-
cal or biological interests (Taher et al., 2011). Benzimidazole
derivatives are structural isosteres of naturally occurring nucle-
otides, which allow them to interact easily with the biomole-
cules in living organisms. Benzimidazole derivatives possess
various biological activities and the optimization of benzimid-
azole-based structures has resulted in various drugs that are
currently in the market, including omeprazole (proton pump
inhibitor), pimobendan (ionodilator), and mebendazole
(anthelmintic) (Starcevic et al., 2007; Alamgir et al., 2007; We-
ber et al., 2007; Spasov et al., 1999). Some recent reports have
focused on the profound anticancer activities shown by benz-
imidazoles and its derivatives, resulting in renewed interest in
this class of molecules. Hoechst 33258 (National Cancer Insti-
tute (NCI) entry number 322921) is a head-to-tail bis-benz-
imidazole compound that speciﬁcally recognizes three
consecutive A:T base pairs in the minor groove of B form
DNA (Seaton et al., 2003). This compound has been serving
as a model compound for biochemical and biophysical studies
of drugs that directly bind to the DNA minor groove, causing
cytotoxicity. 2-Substituted benzimidazoles (bis-benzimidazole
derivatives) were also found to be cytotoxic against breast ade-
nocarcinoma (MCF7) and skin epidermoid carcinoma (A431)
by interfering DNA topoisomerase I activity DNA (Seaton
et al., 2003; Bielawski et al., 2004; Refaat, 2010). Heterocyclic
benzimidazole derivatives bearing amidino substituents at the
C-5 position of a benzimidazole ring and other heterocyclic nu-
clei at the C-2 position showed selectivity toward the MCF7
breast cancer cells (Starcevic et al., 2007).
These broad antitumor properties exhibited by benzimidaz-
oles and our continuing interest in the exploration of novel
heterocyclic scaffolds for anticancer activity (Patel et al.,
2011; Moorthy et al., 2009, 2010) have prompted us to synthe-
size a series of novel benzo[d]imidazole-5-carboxylic acid deriv-
atives and to evaluate these compounds against three breast
cancer cell lines.
2. Materials and methods
All commercially available chemicals and solvents used were of
reagent grade and used without further puriﬁcation. 1H NMR
spectra were obtained with a Bruker Avance II 400 NMR spec-
trometer. Chemical shifts were recorded in parts per million
(ppm) and were reported relative to the TMS. Mass spectral
data were measured on an Applied Biosystem Qtrap 3200
LC-MS/MS system in ESI mode. The IR spectra of the synthe-
sized compounds were recorded on Schimadzu FT-IR 8400S.
Elemental analysis was performed on a Vario Micro cube
CHNS analyzer of Elementar Make. Melting points of thePlease cite this article in press as: Karthikeyan, C. et al., Synthesis and biological e
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point apparatus and are reported uncorrected. Reactions were
monitored by TLC using pre-coated silica gel aluminum plates
(Kieselgel 60, 254, E. Merck, Germany); zones were detected
visually under ultraviolet irradiation.
2.1. General procedure for the synthesis of 1a–1j and 2a–2f
To a solution of aldehyde (2.0 mmol) in 6.5 mL of N,N-di-
methyl acetamide were added 3,4 diamino benzoic acid or its
methyl ester (2.0 mmol) and Na2S2O5 (2.4 mmol). The mixture
was heated to 100 C for 6.5–12 h until TLC conﬁrms the com-
pletion of the reaction. The reaction mixture was then cooled,
diluted with ethyl acetate (5 · 25 mL), dried (MgSO4), and
concentrated in vacuo. The solid obtained was collected on a
sintered-glass ﬁlter and washed with dichloromethane (3x) to
provide the desired compound.
2.1.1. 2-(2-Hydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylic acid (1a)
67% yield; M.P > 300 C; IR (KBr) m (cm1): 3319 (–NH),
3063 (Ar–C–H), 1683 (–C‚O), 1631 (ArC–C), 1261 (–C–N);
1H NMR (400 MHz, DMSO-d6): d (ppm) 12.93 (br, s, 1H,
NH), 8.24 (s, 1H, Ar H), 8.09 (d, 1H, J= 7.6 Hz, Ar H),
7.90 (d, 1H, J= 8.4 Hz, Ar H), 7.73 (d, 1H, J= 8.0 Hz, Ar
H), 7.42 (t, 1H, J= 7.6 Hz, Ar H), 7.03-7.08 (m, 2H, Ar H);
LC–MS analysis (M +H): 255.2 (calculated 254.24); Elemen-
tal Analysis: Calcd. (Found) (%) for C14H10N2O3: C 66.14
(66.18), H 3.96 (3.96), N 11.02 (11.00).
2.1.2. 2-(2,3-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylic acid (1b)
51% yield; M.P. 285 C; IR(KBr) m (cm1): 3284 (–NH), 2989
(Ar–C–H), 1685 (–C‚O), 1622 (ArC–C), 1271 (–C–N); 1H
NMR (400 MHz, DMSO-d6): d (ppm) 13.38 (br, s, 1H,
COOH) 12.81 (br, s, 1H, NH), 9.26 (s, 1H, Ar OH), 8.22 (s,
1H, Ar H), 7.9 (d, 1H, J= 7.6 Hz, Ar H), 7.72 (s, 1H), 7.52
(d, 1H, J= 8 Hz, Ar H), 6.95 (d, 1H, J= 7.6 Hz, Ar H),
6.86 (t, 1H, J= 8 Hz, Ar H); LC–MS analysis (M +H):
271.0 (calculated 270.24); Elemental Analysis: Calcd. (Found)
(%) for C14H10N2O4: C 62.22 (62.27), H 3.73 (3.71), N 10.37
(10.36).
2.1.3. 2-(2,4-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylic acid (1c)
69% yield; M.P. 253 C; IR(KBr) m (cm1): 3242 (–NH), 3076
(Ar–C–H), 1708 (–C‚O), 1614 (Ar C–C), 1267 (–C–N); 1H
NMR (400 MHz, DMSO-d6): d (ppm) 12.78 (br, s, 1H,
NH), 9.66 (s, 1H, OH), 8.19 (s, 1H, Ar H), 7. 75–7.88 (m,
4H, Ar H), 7.55 (s, 1H, Ar H); LC–MS analysis (M +H):
271.2 (calculated 270.24); Elemental Analysis: Calcd. (Found)
(%) for C14H10N2O4: C 62.22 (62.28), H 3.73 (3.70), N 19.27
(19.28).
2.1.4. 2-(2-Hydroxy-3-methoxyphenyl)-1H-benzo[d]imidazole-
5-carboxylic acid (1d)
56% yield; M.P. 273 C; IR (KBr) m (cm1): 3524.06 (–NH),
3068.85 (Ar–C–H), 1683.91 (–C‚O), 1624.12 (Ar–C–C),
1257.63 (–C–N); 1H NMR (400 MHz, DMSO-d6): d (ppm)
13.16 (br, s, 1H, NH) 8.22 (s, 1H, Ar H) 7.88(d, 1H,valuation of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids and its methyl
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Synthesis and biological evaluation of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids 3J= 8.28 Hz, Ar H), 7.58(dd, 2H, J= 7.96, 1.28 Hz, Ar H),
6.98 (dd,1H, J= 8.0, 1.2 Hz, Ar H), 6.88 (t, 1H, J= 7.9 Hz,
Ar H), 3.86 (s, 3H, OCH3); LC–MS analysis (M + H): 285.2
(calculated 284.27); Elemental Analysis: Calcd. (Found) (%)
for C15H12N2O4: C 63.38 (63.43), H 4.25 (4.26), N 9.85 (9.82).
2.1.5. 2-(5-Fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylic acid (1e)
72% yield; M.P. 296 C; IR (KBr) m (cm1): 3321 (–NH), 3080
(Ar–C–H), 1683 (–C‚O), 1259 (–C–N), 1506 (ArC–C); 1H
NMR (400 MHz, DMSO-d6): d (ppm) 13.28 (br, s, 1H,
COOH) 12.71 (br s, 1H, NH), 8.22 (s, 1H, Ar H), 7.83–7.91
(m, 2H, Ar H), 7.63 (s, 1H, Ar H), 6.96–7.13 (m, 2H, Ar H);
LC–MS analysis (M–H): 270.8 (calculated 272.06); Elemental
Analysis: Calcd. (Found) (%) for C14H9FN2O3: C 61.77
(61.76), H 3.33 (3.30), N 10.29 (10.27).
2.1.6. 2-(5-Bromo-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylic acid (1f)
68% yield; M.P. 282 C; IR (KBr) m (cm1): 3238 (–NH), 3068
(Ar–C–H), 1693 (–C‚O), 1622 (Ar C–C), 1257 (–C–N),
1058.42 (–Br); 1H NMR (400 MHz, DMSO-d6): d (ppm)
13.86 (br s, 1H, COOH), 12.93 (br s, 1H, NH), 7.78–8.33 (m,
6H, Ar H); LC–MS analysis (M +H): 335 (calculated
333.14); Elemental Analysis: Calcd. (Found) (%) for
C14H9BrN2O3: C 50.47 (50.50), H 2.72 (2.74), N 8.41 (8.38).
2.1.7. 2-(2-Hydroxy-5-nitrophenyl)-1H-benzo[d]imidazole-5-
carboxylic acid (1g)
58% yield; M.P. 274 C; IR(KBr) m (cm1): 3245 (–NH), 1705
(–C‚O), 1614 (Ar C–C), 1535.39 (NO2), 1288 (–C–N); 1H
NMR (400 MHz, DMSO-d6): d (ppm) 13.76 (br, s, 1H, NH),
9.09 (s, 1H, Ar H) 8.25 (s, 1H, Aromatic CH) 8.16 (dd, 1H,
Aromatic CH J = 2.64 Hz, 9.16 Hz), 7.92 (dd, 1H,
J= 1.28 Hz, 8.48 Hz, Ar H), 7.6 (d, 1H, J= 8.4 Hz, Ar H),
7.1 (d, 1H, J= 9.12 Hz, Ar H); LC–MS analysis (M + H):
300.2 (calculated 299.24); Elemental Analysis: Calcd. (Found)
(%) for C14H9N3O5: C 56.19 (56.18), H 3.03 (3.04), N 14.04
(14.06).
2.1.8. 2-(3,4-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylic acid (1h)
62% yield; M.P. 284 C; IR (KBr) m (cm1): 3342 (–NH), 3068
(Ar–C–H), 1627 (ArC–C), 1294 (–C–N); 1H NMR (400 MHz,
DMSO-d6): d (ppm) 12.68 (br s, 1H, NH), 9.26 (br s, 1H, OH),
8.99 (br s, 1H, OH), 8.12 (s, 1H, Ar H), 7.77 (dd, 1H,
J= 9.76 Hz, 1.36 Hz, Ar H), 7.61 (s, 1H, Ar H), 7.47 (dd,
2H, J= 2.04, 8.24 Hz, Ar H), 6.85 (d, 1H, J= 8.32 Hz, Ar
H); LC–MS analysis (M+ H): 271 (calculated 270.24); Ele-
mental Analysis: Calcd. (Found) (%) for C14H10N2O4: C
62.22 (62.25), H 3.73 (3.71), N 10.37 (10.38).
2.1.9. 2-(4-Hydroxy-3-methoxyphenyl)-1H-benzo[d]imidazole-
5-carboxylic acid (1i)
55% yield; M.P. 257 C; IR (KBr) m (cm1): 3317 (–NH), 3088
(Ar–C–H), 1672 (–C‚O), 1294 (–C–N); 1H NMR (400 MHz,
DMSO-d6): d (ppm) 12.93 (br, s, 1H, NH), 9.41 (s, 1H, OH),
8.14 (s, 1H, Ar H), 7.8 (dd, 1H, J= 8.4 Hz, 1.32 Hz, Ar H),
7.74 (s, 1H, Ar H), 7.61 (d, 1H, J= 8.2 Hz, 1.8 Hz, Ar H),
7.52 (d, 1H, J= 8.3 Hz, Ar H), 6.90 (d, 1H, J = 8.2 Hz, ArPlease cite this article in press as: Karthikeyan, C. et al., Synthesis and biological e
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(calculated 284.27); Elemental Analysis: Calcd. (Found) (%)
for C15H12N2O4: C 63.38 (63.38), H 4.25 (4.26), N 9.85 (9.86).
2.1.10. 2-(3,4,5-Trihydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylic acid (1j)
54% yield; M.P. 267 C; IR (KBr) m (cm1): 3321 (–NH), 3080
(Ar–C–H), 1683 (–C‚O), 1625 (Ar C–C), 1259 (–C–N); 1H
NMR (400 MHz, DMSO-d6): d (ppm) 12.58 (br s, 1H, NH),
8.86 (br s, 2H, OH), 8.42 (br, s, 1H, OH), 8.12 (s, 1H, Ar
H), 7.77 (dd, 1H, J= 8.4 Hz, 1.36 Hz, Ar H), 7.43 (d, 1H,
J= 8.2, Ar H), 7.17 (s, 2H, Ar H); LC–MS analysis
(M +H): 287 (calculated 286.24); Elemental Analysis: Calcd.
(Found) (%) for C14H10N2O5: C 58.74 (58.78), H 3.52 (3.50),
N 9.79 (9.78).
2.1.11. Methyl 2-(2-hydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylate (2a)
67% yield; M.P. 216 C; IR (KBr) m (cm1): 3311 (–NH), 3064
(Ar–C–H), 1720 (–C‚O), 1253 (–C–N), 1213 (–CO–O), 1593
(ArC–C); 1H NMR (400 MHz, DMSO-d6): d (ppm) 13.0 (br
s, 1H, NH), 8.23 (s, 1H, Ar H), 7.96 (d, 1H, J= 7.8 Hz, Ar
H), 7.88(dd, 1H, J= 8.46 Hz, 1.4 Hz, Ar H), 7.58 (d, 1H,
J= 8.6 Hz, Ar H), 7.31 (t, 1H, J= 7.72 Hz, Ar H), 6.97 (d,
1H, J= 8.28 Hz, Ar H), 6.92 (t, 1H, J= 7.72 Hz, Ar H),
3.86 (s, 3H, CH3); LC–MS analysis (M + H): 270.8 (calcu-
lated 272.06); Elemental Analysis: Calcd. (Found) (%) for
C15H12N2O3: C 67.16 (67.10), H 4.51 (4.55), N 10.44 (10.46).
2.1.12. Methyl 2-(2,3-dihydroxyphenyl)-1H-
benzo[d]imidazole-5-carboxylate (2b)
59% yield; M.P. 241 C; IR (KBr) m (cm1): 3298 (–NH), 3078
(Ar–C–H), 1687 (–C‚O), 1271 (–C–N), 1242 (–CO–O), 1539
(ArC–C); 1H NMR (400 MHz, DMSO-d6): d (ppm) 13.12
(br, s, 1H, NH), 8.86 (br, s, 1H, Ar OH), 8.22 (s, 1H, Ar H),
7.88 (dd, 1H, J= 8.42, 1.32 Hz, Ar H), 7.45(dd, 1H,
J= 7.94, 1.32 Hz, Ar H), 6.9 (dd, 1H, J= 7.86,1.32 Ar H),
6.76 (t, 1H, J= 7.88 Hz, Ar H), 3.86 (s, 3H, CH3); LC–MS
analysis (M –H): 282.8 (calculated 284.08); Elemental Analysis:
Calcd. (Found) (%) for C15H12N2O4: C 63.38 (63.35), H 4.25
(4.27), N 9.85 (9.87).
2.1.13. Methyl 2-(2-hydroxy-3-methoxyphenyl)-1H-
benzo[d]imidazole-5-carboxylate (2c)
74% yield; M.P. 234 C (degrades); IR (KBr) m (cm1): 3311
(–NH), 3064 (Ar–C–H), 1720 (–C‚O), 1253 (–C–N), 1593
(ArC–C); 1H NMR (400 MHz, DMSO-d6): d (ppm) 13.21
(br, s, 1H, NH), 8.2 (s, 1H, Ar H), 7.86 (d, 1H, J= 8.48 Hz,
Ar H), 7.56–7.61 (m, 2H, Ar H), 6.98 (d, 1H, J= 7.6 Hz, Ar
H), 6.87 (t, 1H, J= 8.0, Ar H), 3.85 (s, 3H, CH3), 3.83 (s,
3H, OCH3); LC–MS analysis (M +H): 299.0 (calculated
298.1); Elemental Analysis: Calcd. (Found) (%) for
C16H14N2O4: C 64.42 (64.40), H 4.73 (4.75), N 9.39 (9.38).
2.1.14. Methyl 2-(2-hydroxy-5-nitrophenyl)-1H-
benzo[d]imidazole-5-carboxylate (2d)
63% yield; M.P. 223 C; IR (KBr) m (cm1): 3302 (–NH), 3008
(Ar–C–H), 1708 (–C‚O), 1278 (–C–N), 1220 (–CO–O), 1591
(Ar C–C); 1H NMR (400 MHz, DMSO-d6): d (ppm) 13.16
(br s, 1H, NH), 8.41 (s, 1H, Ar H), 8.23 (s, 1H, Ar H), 7.87valuation of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids and its methyl
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1H, J= 7.6 Hz, Ar H), 3.85 (s, 3H, CH3); LC–MS analysis
(M+ H): 314.0 (calculated 313.07); Elemental Analysis: Calcd.
(Found) (%) for C15H11N3O5: C 57.51 (57.55), H 3.54 (3.52), N
13.41 (13.40).
2.1.15. Methyl 2-(5-ﬂuoro-2-hydroxyphenyl)-1H-
benzo[d]imidazole-5-carboxylate (2e)
72% yield; M.P. 239 C; IR (KBr) m (cm1): 3333 (–NH), 3057
(Ar–C–H), 1722 (–C‚O), 1255 (–C–N), 1213 (–CO–O) 1535
(ArC–C); 1H NMR (400 MHz, DMSO-d6): d (ppm) 13.12 (br
s, 1H, NH), 8.22 (s, 1H, Ar H), 7.82–7.88 (m, 2H, Ar H),
7.67(s, 1H, Ar H), 6.96–7.12 (m, 2H, Ar H), 3.85 (s, 3H,
CH3); LC–MS analysis (M+ H): 285.0 (calculated 286.08);
Elemental Analysis: Calcd. (Found) (%) for C15H11FN2O3: C
62.94 (62.90), H 3.87 (3.89), N 9.79 (9.80).
2.1.16. Methyl 2-(3,4-dihydroxyphenyl)-1H-
benzo[d]imidazole-5-carboxylate (2f)
54% yield; M.P 228 C; IR (KBr) m (cm1): 3363 (–NH),
3282 (–OH), 1701 (–C‚O), 1259 (–C–N), 1211 (–CO–O),
1600 (ArC–C); 1H NMR (400 MHz, DMSO-d6): d (ppm)
13.16 (br s, 1H, NH), 10.21 (br s, 1H, Ar OH), 9.57 (br,
s, 1H, Ar OH), 8.29 (s, 1H, Ar H), 8.06 (dd, 1H,
J= 8.52,1.4 Hz, Ar H), 7.68 – 7.77 (m, 3H, Ar H), 7.02
(d, 1H, J= 8.4), 3.87 (s, 3H, CH3); LC–MS analysis
(M + H): 283.0 (calculated 284.08); Elemental Analysis:
Calcd. (Found) (%) for C15H12N2O4: C 63.38 (63.35), H
4.25 (4.27), N 9.85 (9.86).
2.2. Anticancer activity evaluation
2.2.1. Cell lines
The human MDA-MB468, MDA-MB231 and MCF-7 breast
cancer cell lines were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum (Hyclone, Logan
UT) and 2 mM L-glutamine. Cells were grown at 37 C with
5% CO2, 95% air under the humidiﬁed conditions. The stock
solution was diluted in culture medium (0.1–100 lM) immedi-
ately before use. The ﬁnal concentration of DMSO in the
SRB-based cytotoxicity assays did not exceed 0.1%. To rule
out that the DMSO concentration used may affect cell cyto-
toxicity, culture medium containing equivalent concentration
of DMSO was used as a negative control in all experiments.
In all studies, the concentration of DMSO used did not
notably show any cytotoxicity.
2.2.2. Reagents
Cisplatin was purchased from Sigma–Aldrich Canada Ltd
(Oakaville, ON, Canada). All the compounds were dissolved
in 10–20 mM dimethyl sulfoxide (DMSO) and stored at
20 C until use. The stock solution was diluted in culture
medium (0.1–100 lM) immediately before use. The ﬁnal
concentration of DMSO in the SRB-based cytotoxicity as-
says did not exceed 0.1%. To rule out that the DMSO con-
centration used may affect cell cytotoxicity, culture medium
containing equivalent concentration of DMSO was used as
a negative control in all experiments. In all studies, the
concentration of DMSO used did not notably show any
cytotoxicity.Please cite this article in press as: Karthikeyan, C. et al., Synthesis and biological e
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Cytotoxic effects were determined by a Sulforhodamine B
(SRB)-based protocol (Solomon et al., 2009; Vichai and Kirti-
kara, 2006). For a typical screening experiment, 5,000–10,000
cells were inoculated into 100 lL medium per well of a 96-well
microtiter plate as described previously (Solomon et al., 2009;
Skehan et al., 1990; Vichai and Kirtikara, 2006). Brieﬂy, after
the inoculation, the microtiter plate was incubated at 37 C,
5% CO2, 95% air and 100% relative humidity for 24 h, prior
to the addition of experimental drugs. Some of the sample
wells were ﬁxed with 25 lL of 50% trichloroacetic acid
(TCA) as a control of the cell population for each cell line at
the time of drug addition (Tz). An aliquot of the frozen stock
was thawed and diluted to the desired ﬁnal maximum test-con-
centration with complete medium. Two- to ten-fold serial
dilutions were made to provide a total of seven drug concen-
trations (and a control [C]). Following the addition of drugs,
the culture plate was incubated for additional 48 h. Cells were
ﬁxed in situ by slowly adding 25 lL of cold 50% (w/v) TCA
(ﬁnal concentration, 10% TCA), and were then incubated
for 60 min at 4 C. The supernatant was discarded, and the
plate was washed ﬁve times with tap water, followed by air-
drying. 50 lL of SRB solution at 0.4% (w/v) in 1% acetic acid
was added to each well, and the plate was incubated for
>30 min at room temperature. Unbound SRB was removed
by ﬁve washes with tap water, followed by air-drying. The cells
‘‘stained’’ with SRB were solubilized with 10 mM trizma base,
and the absorbance was read on an automated plate reader at
a wavelength of 515–564 nm. The relative growth rate (%) was
calculated for each of the compound concentrations according
to the following formula:
ðTi TzÞ=ðC TzÞ  100 ð1Þ
In the formula, Tz denotes time zero, C denotes control
growth and Ti denotes the OD for different concentrations
of tested compounds. The GI50 for each compound was ob-
tained from a non-linear Sigmoidal dose–response (variable
slope) curve which is ﬁtted by GraphPad Prism v.4.03 soft-
ware. Values were calculated for each of these parameters if
the level of activity was reached. However, if the effect was
not reached or was exceeded, the value for that parameter
was expressed as greater or less than the maximum or mini-
mum concentration tested.3. Results and discussion
The synthesis of (2-(hydroxyphenyl)-3H-benzo[d]imidazole-5-
carboxylic acids was accomplished with the method reported
by Scheme 1 (Arienti et al., 2005). The compounds 1a–1j were
obtained by condensing equimolar quantities of commercially
available hydroxy benzaldehydes with 3-, 4-diamino benzoic
acid in dimethyl acetamide in the presence of sodium metabi-
sulﬁte (Na2S2O5) at 100 C. The structures of synthesized com-
pounds were determined using different spectroscopic
techniques, including 1H NMR, IR, and LC–MS analyses
and elemental analysis.
The synthesized (2-(hydroxyphenyl)-3H-benzo[d]imidazole-
5-carboxylic acids and its methyl esters were evaluated for
their antiproliferative activity against a panel of three breast
cancer cell lines: MDA-MB468 (a PTEN defective, intermedi-
ately differentiated, EGFR positive breast adenocarcinomavaluation of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids and its methyl
p://dx.doi.org/10.1016/j.arabjc.2013.07.003
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Scheme 1 Synthesis of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids and its methyl ester derivatives.
Table 1 Structure and anti-breast cancer activity of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids (1a–1j) and its methyl ester
derivatives (2a-2f).
N
N
H
HO
O
R
 (1a to 1j)
N
N
H
O
O
R
(2a-2f)
.Code GI50 (lM)
a,b
MDA-MB231 MDA-MB468 MCF7
1a 2-OH 42.21 122.05 48.48
1b 2,3-di OH 65.53 91.91 70.45
1c 2,4-di OH 75.61 101.35 98.48
1d 2-OH, 3-OMe 70.73 83.26 26.48
1e 2- OH, 5-F 33.25 29.14 25.47
1f 2-OH, 5-Br 85.21 75.65 73.69
1g 2-OH,5-NO2 56.23 48.57 34.21
1h 3,4-di OH 12.85 11.85 9.23
1i 3 MeO, 4-OH 25.87 21.98 18.68
1j 3,4,5-tri OH 46.32 98.25 75.36
2a 2-OH 95.26 85.08 74.12
2b 2,3-di OH 11.25 4.01 3.70
2c 2-OH, 3-OMe 12.35 11.52 9.52
2d 2-OH,5-NO2 3.57 4.03 7.79
2e 2- OH, 5-F 6.23 4.09 0.18
2f 3,4-di OH 34.20 26.46 19.84
Ref. Cisplatin 23.65 31.02 25.77
a GI50 values were calculated from Sigmoidal dose response curves (variable slope), which were generated with GraphPad Prism V. 4.02
(GraphPad Software Inc.).
b Values are the mean of triplicates of at least two independent experiments.
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negative basal-like breast cancer) and MCF7 (well differenti-
ated, p53+/, invasive ductal breast carcinoma). Each
compound stored at 20 mM was diluted from 100 lM to
0.0064 lM by ﬁvefold serial dilutions. Cells were treated with
each compound for 48 h, followed by measuring cell growth
rates by SRB-based spectrophotometry. The reading of SRB
staining value is known to accurately reﬂect the levels of total
cellular macromolecules/cell growth/proliferation (Skehan
et al., 1990). The GI50 concentration for each compound was
calculated with reference to a control sample, which represents
the concentration that results in a 50% decrease in cell growth/
proliferation after 48 h incubation in the presence of the drug.
For each compound, GI50 was deduced from Sigmoidal dose–Please cite this article in press as: Karthikeyan, C. et al., Synthesis and biological e
esters as potent anti-breast cancer agents. Arabian Journal of Chemistry (2013), httresponse curves that were generated with data obtained from
two independent experiments carried out each in triplicate
and presented in Table 1. The data of cisplatin was included
as reference standard. The resultant data showed that, among
16 compounds studied, eight compounds exhibited substantial
antiproliferative effects on all three breast cancer cell lines
examined. The results also indicated that the methyl esters
(2) showed greater growth inhibitory potency than free carbox-
ylic acid derivatives (1).
Among benzo[d]imidazole-5-carboxylic acids, compounds
with the 2-hydroxyl group in the aryl ring (1a–g) were the least
potent with an exception of compound 1e which showed an
inhibitory proﬁle comparable to cisplatin. Compound 1a with
a hydroxyl group at the ortho position of the aryl ring showedvaluation of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids and its methyl
p://dx.doi.org/10.1016/j.arabjc.2013.07.003
6 C. Karthikeyan et al.GI50 values of 50 lM against MDA-MB231 and MCF7 and
122 lM against MDA-MB468. Introduction of an additional
hydroxyl group in compound 1a either at meta (1b) or para po-
sition (1c) of the aryl ring resulted in decreased antiprolifera-
tive effects on all the three cancer cells. Substitution of the 3-
methoxy group in compound 1a slightly improved the growth
inhibitory potency against MDA-MB468 and MCF7 cells.
Fluorine substitution at the ﬁfth position of the aryl rings
(1e) resulted in a marked increase in the anti proliferative
activity against the three breast cancer cells. However, replace-
ment of ﬂuorine by a larger halogen atom, bromine (1f) led to
marked reduction of antiproliferative effect on MDA-MB231
and MCF7 cells. Introduction of the electron withdrawing ni-
tro group at ﬁfth position of the aryl ring (compound 1g) re-
sulted in modest improvement in the growth inhibitory
activity against MDA-MB468 and MCF7 cells.
Compound 1h with 3, 4-dihydroxyl substitution in the aryl
ring was found to be the most potent with GI50 values of 12.85,
11.85 and 9.23 lM against MDA-MB468, MDA-MB231 and
MCF breast cancer cells respectively. Introduction of an addi-
tional hydroxyl group in the aryl ring to give a trihydroxyl
derivative 1j led to a drastic reduction in antiproliferative
activity. Compound 1i which is a mono methylated derivative
of compound 1h showed a one fold decrease in antiprolifera-
tive potency against the three breast cancer cells.
Benzo[d]imidazole-5-carboxylic acids showed only modest
potency against the studied breast cancer cell lines contrary
to our expectations. The poor anti-breast cancer proﬁle exhib-
ited these compounds which may be due to the ionization of
free carboxylic acid moiety to a charged carboxylate anion in
aqueous conditions hence impeding the cellular permeability
of these studied compounds. A similar phenomenon was re-
corded by Gowda et al. (2009) and they had overcome this
problem by transformation of the free carboxylic group to
an ester. Related to the foregoing, methyl ester analogs of
the benzo[d]imidazole-5-carboxylic acid were synthesized and
subsequently evaluated for their antiproliferative effects on
the breast cancer cells. The esteriﬁcation of the carboxylic
group in the title compounds led to mixed results. The esteriﬁ-
cation caused a dramatic increase in the cytotoxicity to the
majority of compounds (2b–2e) while decreasing potency to
a few compounds (2a and 2f). Compound 2e, the methyl ester
derivative of 2-(5-ﬂuoro-2-hydroxyphenyl)-1H-benzo[d]imid-
azole-5-carboxylic acid (1e) displayed excellent growth inhibi-
tory activity against estrogen receptor dependent MCF7 cell
line in submicromolar concentration (GI50 = 0.18 lM) which
is greater than a hundred fold improvement than its unesteri-
ﬁed counterpart (1e). Furthermore, esteriﬁcation also im-
proved the antiproliferative activity of compound 1e against
MDA-MB231 and MDA-MB468 cells by greater than ﬁvefold.
Compound 2d with 2-hydroxy, 5-nitro substitutions in the phe-
nyl ring showed greater potency (GI50 < 5 lM) against the ER
negative MDA-MB231 and MDA-MB468 cells than the ER-
positive MCF7. Another ester derivative with comparable
antiproliferative activity proﬁle is compound 2b with 2-, 3-
dihydroxy substitution in the phenyl ring. Compound 2b
shows greater potency than reference standard cisplatin, as
its GI50 values were 11.25, 4.01 and 3.70 lM against MDA-
MB231, MDA-MB468 and MCF7 cells lines, respectively.
Compound 2f with 2-hydroxyl and 3-methoxyl substitutions
in the phenyl ring exhibited greater cytotoxic potency than
the corresponding free carboxylic derivative 1d or cisplatin.Please cite this article in press as: Karthikeyan, C. et al., Synthesis and biological e
esters as potent anti-breast cancer agents. Arabian Journal of Chemistry (2013), httSurprisingly, Compound 2f, the methyl ester analog of com-
pound 1h did not show any improved antiproliferative activity.
4. Conclusion
In conclusion, various substituted 2-(phenyl)-3H-
Benzo[d]Imidazole-5-carboxylic acids (1a–1j) and its methyl es-
ters (2a–2f) were prepared by condensing equimolar quantities
of commercially available hydroxy benzaldehydes with 3-, 4-
diamino benzoic acid and its methyl ester and then screened
for their antiproliferative activity on breast cancer cell lines
(MDA-MB231, MDA-MB468 and MCF7) in vitro. Almost
50% of the compounds synthesized showed either comparable
to or greater potency than cisplatin, the compound that we used
as a reference. Among the carboxylic acid derivatives, com-
pound 1h with 3, 4 dihydroxy substitution in the aryl ring is
the most active with GI50 values of 12.85, 11.85 and 9.23 lM
against MDA-MB468, MDA-MB231 andMCF7 breast cancer
cells respectively. Among the methyl ester derivatives, com-
pound 2e with 2-hydroxyl and 5-ﬂuoro substitution in the aryl
ring was the most potent with GI50 values of 6.23, 4.09 and
0.18 lm against MDA-MB468, MDA-MB231 andMCF breast
cancer cells respectively. Taken together, our data suggest that
the title compounds particularly compounds 1h and 2e, can be
promising lead compounds in the development ofmore effective
cancer therapeutics for treatment of breast cancer.
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